Ipilimumab
Based on 4 publication(s) in Google Scholar
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies.
For research use only. We do not sell to patients.
- Purity: 99.83%
- CAS No.: 477202-00-9
- Molecular Weight:145.38 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ipilimumab
More
Customer Validation & Images
-
Flow Cytometry
-
Flow Cytometry
-
Flow Cytometry
-
Flow Cytometry
-
Flow Cytometry
Biological Activity
Human IgG1 kappa
Human
CTLA4
Ipilimumab inhibits CTLA-4, allowing the T cell immune response to be reactivated against tumor cells. Ipilimumab can promote antitumor activity as a single agent or in combination with cytokines, chemotherapy, or vaccines[1].
Ipilimumab (0, 5 or 50 μg/ mL, 6 days) alone can enhance IL-2 production and in combination with nivolumab stimulate higher IL-2 release in peripheral blood mononuclear cells (PBMC). And the combination of ipilimumab and nivolumab treatment synergistically enhances effector and memory T-cell responses[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Ipilimumab has a significant CDC effect on CHOK1-human CTLA4 cells in a dose-dependent manner.The EC50 for this effect is 604 ng/mL.
Chemical Information
-
CAS No. 477202-00-9
-
Appearance Liquid
-
Molecular Weight 145.38 kDa
-
Color Colorless to light yellow
-
SMILES
[Ipilimumab]
-
Synonyms
MDX-010; BMS-734016
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3. [Abstract]2024 Mar 22;15(1):2567. PMID: 38519469 -
Am J Hematol
Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts. [Abstract]2024 Oct;99(10):1939-1950. PMID: 38953347
Ipilimumab purchased from MedChemExpress. Usage Cited in: Am J Hematol. 2024 Oct;99(10):1939-1950. [Abstract]
Ipilimumab (α-CTLA-4) (10 mg/kg; i.p.; once a week for 4 weeks) treatment dramatically decreased granulocyte numbers in the spleen (SP) and bone marrow (BM) as well as monocyte numbers in the bone marrow (BM) of PDX mice.
Ipilimumab purchased from MedChemExpress. Usage Cited in: Am J Hematol. 2024 Oct;99(10):1939-1950. [Abstract]
Ipilimumab (α-CTLA-4) (10 mg/kg; i.p.; once a week for 4 weeks) enabled detection of human CD3+ T cells exclusively in the spleen (SP) and bone marrow (BM) of treated animals.
Ipilimumab purchased from MedChemExpress. Usage Cited in: Am J Hematol. 2024 Oct;99(10):1939-1950. [Abstract]
Ipilimumab (α-CTLA-4) (10 mg/kg; i.p.; once a week for 4 weeks) decreased CD34+ cells among human CD45 + CD3- cells in bone marrow (BM) of PDX mice.
Ipilimumab purchased from MedChemExpress. Usage Cited in: Am J Hematol. 2024 Oct;99(10):1939-1950. [Abstract]
Ipilimumab (α-CTLA-4) (10 μg/mL) showed efficacy in reactivating MF T-cell response in the presence of myeloid cells, as demonstrated by the increased percentage of OX40-positive CD3+CD8+ T cells compared to isotype control-treated samples.
Ipilimumab purchased from MedChemExpress. Usage Cited in: Am J Hematol. 2024 Oct;99(10):1939-1950. [Abstract]
Ipilimumab (α-CTLA-4) (10 μg/mL) elicited a significant T cell-mediated killing of CD14+ and CD15+ myeloid populations in the CD3- live cells fraction (0.41 and 0.27 fold reduction, respectively).
-
J Biomed Inform
2023 Jun:142:104383. PMID: 37196989 -
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Movva S, et al. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther. 2009 Feb;9(2):231-41. [Content Brief]
[2]. Mark J Selby, et al. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One. 2016 Sep 9;11(9):e0161779. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz